2 weeks Ago By Defense World Staff
Townsquare Capital LLC boosted its position in Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ) by 79.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,540 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,568 shares during the quarter.
Townsquare Capital LLC’s holdings in Jazz Pharmaceuticals were worth $436,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 1.
5% during the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock worth $311,699,000 after acquiring an additional 37,108 shares in the last quarter. Pacer Advisors Inc.
raised its holdings in Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc.
now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Jazz Pharmaceuticals by 4.
8% in the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company’s stock valued at $195,506,000 after buying an additional 72,007 shares in the last quarter.
Franklin Resources Inc. grew its position in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter.
Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after buying an additional 48,708 shares during the last quarter. Finally, Charles Schwab Investment Management Inc.
raised its stake in Jazz Pharmaceuticals by 15.8% during the 4th quarter. Charles Schwab Investment Management Inc.
now owns 615,517 shares of the specialty pharmaceutical company’s stock worth $75,801,000 after acquiring an additional 83,807 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.
Analyst Ratings Changes A number of equities analysts have recently commented on the stock. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.
00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the company from $140.00 to $150.
00 in a report on Wednesday, February 26th. Morgan Stanley restated an “overweight” rating and issued a $183.00 price target (up previously from $175.
00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $220.00 to $230.
00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, April 10th.
One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $187.
71. Insider Activity In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Tuesday, April 1st.
The stock was sold at an average price of $123.75, for a total value of $185,625.00.
Following the completion of the sale, the chief executive officer now owns 440,307 shares of the company’s stock, valued at $54,487,991.25. This trade represents a 0.
34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link . Also, CAO Patricia Carr sold 1,140 shares of the company’s stock in a transaction on Monday, March 10th.
The shares were sold at an average price of $137.81, for a total value of $157,103.40.
Following the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. The trade was a 13.
98 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last 90 days, insiders sold 28,736 shares of company stock worth $4,023,305.
Insiders own 4.20% of the company’s stock. Jazz Pharmaceuticals Trading Up 1.
2 % Jazz Pharmaceuticals stock opened at $102.78 on Monday. Jazz Pharmaceuticals plc has a 12-month low of $95.
49 and a 12-month high of $148.06. The stock has a market capitalization of $6.
24 billion, a PE ratio of 14.48, a price-to-earnings-growth ratio of 1.04 and a beta of 0.
42. The firm has a 50 day simple moving average of $127.60 and a 200-day simple moving average of $122.
50. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.
26 and a quick ratio of 3.74. Jazz Pharmaceuticals Profile ( Free Report ) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Featured Articles Five stocks we like better than Jazz Pharmaceuticals 5 discounted opportunities for dividend growth investors With a 60%+ Upside, There’s Plenty to Love About Lovesac The Most Important Warren Buffett Stock for Investors: His Own J.B.
Hunt Transport Overcorrects Into a Buying Opportunity Options Trading – Understanding Strike Price AppLovin: Can Record Profits Overcome Market Skepticism? Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ). Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
